Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Three Are Thwarted In Latest Lacosamide Gambit In US

Executive Summary

Three generics firms have failed in their latest attempt to invalidate a patent protecting UCB’s lacosamide-based Vimpat epilepsy brand until 2022.

You may also be interested in...

What’s Next? Five Things To Look Out For In March

This month, generic competition to several lucrative brands, not least Bristol Myers Squibb’s $8.7bn Revlimid, are set to fall to generic competition in the US. Meanwhile, Sawai is looking to close on a key deal.

AAM Weighs In On Supreme Court Challenge To UCB’s Lacosamide

Throwing its weight behind a US Supreme Court petition from Alembic, Mylan and Sun Pharma, local industry association the AAM has insisted that the top US court should correct the ‘lead compound test’ imposed by the Court of Appeals for the Federal Circuit and replace it with the statutory obviousness test.

Leading players lose US lacosamide appeal

Several of the world’s leading generics players, including Teva, Mylan, Apotex and Aurobindo, have failed to convince the US Court of Appeals that the sole US patent listed against UCB’s Vimpat (lacosamide) tablets is invalid. Reissued US drug-substance patent RE38,551 protects until 17 March 2022 the Vimpat epilepsy brand that experienced a 19% rise in US sales last year to C746 million (US$874 million).


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts